Document is current
Any future updates will be listed below
-
Authors
Saag, K. https://orcid.org/0000-0001-6189-8078
Cosman, F. https://orcid.org/0000-0003-4554-6616
De Villiers, T.
Langdahl, B. https://orcid.org/0000-0002-8712-7199
Scott, B.B.
Denker, A.E.
Pong, A. https://orcid.org/0000-0002-3377-5318
Santora, A.C. https://orcid.org/0000-0001-6040-7935
-
Funding
Funding for this research was provided by:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- License Information
-
More Information
Article History
Received: 17 January 2020
Accepted: 7 December 2020
First Online: 19 February 2021
Compliance with ethical standards
:
: Boyd B Scott, Annpey Pong, Andrew Denker, and Arthur C Santora are, or were at the time of study conduct, employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD), and may own stock and/or stock options in Merck & Co., Inc., Kenilworth, NJ, USA. Arthur C. Santora is Chief Medical Officer, Entera Bio Ltd. Kenneth Saag was a past consultant and investigator for MSD and has served as a consultant and investigator for Amgen, MSD, and Radius. Felicia Cosman was a consultant and advisor for MSD and is a consultant, advisor, and speaker for Amgen, Lilly, and Radius. Tobias De Villiers has participated in speaker panels for Abbott, Adcock Ingram, Aspen, MSD, and Pfizer Inc. Bente Langdahl was an advisor for MSD, is an advisor for Amgen, Lilly, and UCB, and has received research grants (for her institution) from Amgen and Novo Nordisk.
